GLP-1s & Breast Cancer: What the New Research Really Says

A new Penn Medicine study is making headlines after researchers found that women taking GLP-1 medications had about 30% lower odds of being diagnosed with breast cancer compared to similar women who were not taking these medications. So what does that actually mean? In this episode, we separate the headlines from the science and explain why researchers are excited, while also discussing what we still don't know. In this episode, we break down: • What the new Penn Medicine breast cancer study actually found • Why a 30% lower risk does not mean 30 out of 100 women avoided breast cancer • How obesity, insulin resistance, inflammation, and estrogen influence breast cancer risk • The biologic reasons GLP-1 medications may help reduce cancer risk • The important limitations of this research and why it does not prove cause and effect • What these findings could mean for women with obesity, insulin resistance, or a family history of breast cancer The most exciting part of this research isn't that we suddenly have a new breast cancer prevention drug. It's that improving metabolic health may impact far more than the number on the scale. As always, we'll discuss what the evidence supports today, what questions remain unanswered, and where the research is headed next. Share this with someone who's been seeing the headlines and wondering what they really mean. #HumpDayHormones #GLP1 #BreastCancerResearch #Semaglutide #Tirzepatide #WomensHealth #HormoneHealth #MetabolicHealth #BreastCancerAwareness #MedicalResearch